SMAD5 and chronic kidney disease: Compared with the CKD-AVF group, Sal B inhibited the expression of BMP-2, p-Smad1, p-Smad5, Osterix, and Runx2 in a dose-dependent manner, indicating that Sal B inhibited the activation of BMP2/Smads signaling pathway in CKD-AVF model.